Published: 01-12-2024 12:32 | Updated: 01-12-2024 12:37

GH-Pharma group at GPH coordinates the EU MAV+ project in Rwanda

Eighteen persons standing in front of a building and a statue with gorillas.
Professor Eleni Aklillu and other participants from the Curriculum department workshop, held in Rwanda in November. Photo: N/A.

Professor Eleni Aklillu, GH-Pharma research group leader at the Department of Global Public Health, is leading the coordination of the EU MAV+ project in Rwanda. Sweden is part of the Team Europe initiative with a total budget of €10 million, managed by Sida.

Funded by the European Union, the Team Europe Initiative on Manufacturing and Access to Vaccines, Medicines, and Health Technologies in Africa (EU MAV+ initiative) aims to enhance vaccine biomanufacturing and access to essential health products across Africa. Sweden is part of the Team Europe initiative, managing a total budget of €10 million through Sida.

Three Swedish universities are key partners in the project: Karolinska Institutet (KI), Gothenburg University, and Umeå University, collaborating closely with the University of Rwanda. On behalf of these Swedish institutions, GPH has signed a grant agreement of around 2 million SEK to fund the six-month inception phase of the project.

During this phase, key activities include the preparation of a logical framework and detailed work plan for the next four years of the project. Additional milestones include the development of a PhD program in Medical and Health Sciences and the creation of an MSc curriculum in Clinical Trials. Professor Eleni Aklillu is actively involved in driving the project's implementation.